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Obesity is associated with insulin resistance, disturbed glucose homeostasis, low grade inﬂammation, and comorbidities such
as type 2 diabetes and cardiovascular disease. The cytokine macrophage migration inhibitory factor (MIF) is an ubiquitously
expressedproteinthatplaysacrucialroleinmanyinﬂammatoryandautoimmunedisorders.IncreasingevidencesuggeststhatMIF
also controls metabolic and inﬂammatory processes underlying the development of metabolic pathologies associated with obesity.
This is a comprehensive summary of our current knowledge on the role of MIF in obesity and obesity-associated comorbidities,
based on human clinical data as well as animal models of disease.
1.Introduction
The incidence of obesity is increasing in many populations
in the world and in some regions now aﬀects more than
30% of adults [1]. Increased adipose tissue mass, especially
in the abdominal region, is associated with insulin resistance
and disturbed glucose homeostasis (dysmetabolic state),
and comorbidities such as type 2 diabetes (T2D) and
cardiovascular disease [2, 3]. Visceral adiposity is considered
to be a marker of the dysmetabolic state, reﬂecting the
inability of subcutaneous adipose tissue to act as a protective
metabolic sink for the clearance and storage of dietary
triglycerides. Recent advances in our understanding of
adipose tissue biology have provided evidence for a more
causative role of obesity in the etiology of its comorbidities.
Increased fat mass is associated with increased macrophage
inﬁltration, increased release of cytokines, adipokines, and
free fatty acids (FFAs) from adipocytes and/or activated
macrophages, and local insulin resistance [4]. The release
of cytokines/adipokines and FFA into the circulation allows
their transport to the liver, heart, aorta, and skeletal mus-
cle, often promoting reduced insulin sensitivity and local
inﬂammation in these organs [5]. Tissue-speciﬁc insulin
resistance is thought to further enhance a proinﬂamma-
tory condition because insulin itself can exert antilipolytic
and anti-inﬂammatory eﬀects. On the systemic level, this
proinﬂammatory condition is reﬂected by elevated levels
of cardiometabolic risk factors including C-reactive protein
(CRP), ﬁbrinogen and serum amyloid A (SAA), and by
circulatingmononuclearcellsthatexhibitaproinﬂammatory
status.
Macrophage migration inhibitory factor (MIF) is an
innate cytokine involved in many inﬂammatory and autoim-
mune disorders; many of these pathologies are associated
with obesity including cardiovascular [6] and kidney disease
[7]. MIF is widely expressed in numerous types of tissue and
it regulates acute inﬂammatory as well as adaptive immune
reactions [8, 9]. Increasing evidence suggests that MIF also
controls metabolic and inﬂammatory processes underlying
the development of metabolic disorders such as glucose
homeostasis during periods of stress and macrophage inﬁl-
tration into adipose tissue. This survey summarizes our
current knowledge on the role of MIF in obesity-associated
comorbidities, based on clinical and research data.
2.HumanStudies
2.1. MIF and Obesity. Obesity and speciﬁcally the enlarge-
ment of the abdominal adipose depots are considered major
risk factors for the development of insulin resistance, T2D,2 Mediators of Inﬂammation
and diabetic complications. Several lines of clinical evidence
support a relationship between MIF and obesity (Table 1).
Dandona et al. reported a correlation between serum MIF
levels and the body mass index (BMI) [10]. Obese subjects
with an average BMI of 37.5 ± 4.9kg/m 2 had a signiﬁcant
higher fasting MIF concentration (2.8 ± 2.0ng/mL) than
healthy lean control subjects (BMI 22.6 ± 3.4kg/m 2;1 .2 ±
0.6ng/mL) [10]. MIF mRNA expression in mononuclear
cells (MNCs) was also signiﬁcantly greater (by 60%) in the
obese and related to plasma FFA concentrations and BMI
but not to plasma MIF concentrations or HOMA-index. The
authors showed that 6 weeks of metformin treatment (obese
subjects only) lowered MIF plasma levels in the absence
of an eﬀect on plasma glucose, insulin, and FFA. After
withdrawal of the drug, MIF levels returned to their initial
value indicating a metformin-speciﬁc eﬀect. Other studies
conﬁrmed elevated plasma MIF levels in the obese compared
to lean subjects [11, 12]a sw e l la si n c r e a s e dM I Fm R N A
expression in MNC [11]. In line with these observations,
severely obese but otherwise healthy subjects (BMI 43.0 ±
8.6kg/m 2) participating in a diet and physical activity-based
weight management program showed decreased plasma MIF
levels (39% decrease) after weight loss of 14.4kg [13]. In
another weight loss program (4.4kg weight loss), a 67%
decrease in circulating MIF was reported [14]. In contrast to
these studies however, morbid obese subjects (BMI 46.7 ±
5.8kg/m 2) displayed relatively low baseline plasma MIF
levels (about 0.2 ± 0.4ng/mL)[15]. After gastric restrictive
surgery, the BMI decreased markedly (33 ± 4.8BMIkg/m 2)
in these patients while MIF concentrations remained stable
and low for the ﬁrst 6 months. Then, following weight
loss, MIF levels began to increase and reached the levels of
lean individuals (0.71 ± 0.58ng/mL) within 12 weeks after
surgery.
The results of the above studies evaluating the relation-
ship between obesity and MIF are not uniform and any
causal relationship between obesity and MIF levels remains
to be established. Factors that may contribute to the large
variability between the studies include diﬀerences in gender
(plasma MIF levels are higher in males [16]), the use of
hormone replacement therapy (HRP; woman with HRP
show 2-3 fold higher plasma MIF levels [13]), circadian
rhythm [17], and diﬀerences in MIF promoter genotypes
causing diﬀerences in promoter activity. Functional MIF
promoter alleles which include a variable nucleotide tandem
repeat (−794CATT5–8)[ 18] and associated single nucleotide
polymorphisms (SNP) have been identiﬁed [19, 20]a n d
recent studies have linked the diﬀerences in MIF serum levels
between male and female subjects to speciﬁc SNPs [16, 21].
2.2. Studies in Diabetic Patients. Recent epidemiological data
provide support for a role for MIF in the development of IR
and T2D in humans (Table 2). Compared to normal healthy
control subjects, patients with T2D displayed signiﬁcantly
elevated serum MIF levels [24]. MIF was not correlated
with plasma glucose, HbA1c, and diabetes duration. The
American Pima Indians, which have been intensively studied
because of their high incidence of T2D diabetes also show
elevatedcirculatinglevelsofMIF[25].Herderandcoworkers
reported a signiﬁcant increase of circulating MIF, CRP,
and interleukin-6 (IL-6) in subjects with impaired glucose
tolerance (IGT; n = 242) or T2D (n = 236) compared
to normoglycemic controls (n = 244) (KORA S4 study;
participants aged 55–74 years) [26]. The strong positive
associationbetweensystemicconcentrationsofMIFandIGT
and T2D was independent of the other immune mediators.
In contrast to CRP and IL-6, there was a highly signiﬁcant
increase in MIF concentrations in the T2D group compared
with the IGT group suggesting that elevations of systemic
MIF concentrations precede the onset of T2D.
AdditionalsupportforacausalroleofMIFintheetiology
of T2D comes from a population-based study comparing the
eﬀect of four SNPs of MIF (rs755622, rs2070766, rs2070767,
and rs1007888) on serum concentrations and the risk of
T2D (MONICA/KORA Augsburg Study) [16]. The C allele
of SNP rs1007888 was associated with increased circulating
MIF independent of age, sex, BMI, blood pressure, TC/HDL
cholesterol, CRP, IL-6, smoking status, physical activity,
time of blood draw. Female subjects with MIF genotype
rs1007888CC had an increased risk of T2D [16]. The associ-
ation between MIF levels and incident T2D was signiﬁcantly
higher in obese women compared with nonobese ones.
Diﬀerent results were obtained in the Finnish Diabetes
Prevention Study (n = 522; 40–65 years old) which tested
lifestyleinterventioninoverweightorobesemenandwomen
with impaired glucose tolerance (IGT) and BMI > 25kg/m2
[27]. MIF was not associated with the risk of T2D in the
untreated control group of this study. In the intervention
group, subjects with high MIF and low RANTES levels had
a lower risk of T2D (sexes were not analyzed separately in
this study).
Elevated levels of MIF or its cell surface receptor (CD74)
were found in patients with diabetic complications including
diabetic nephropathy [24, 28], diabetic retinopathy [24, 29,
30], and diabetic foot syndrome [31] further supporting
a role of MIF in the comorbidities of obesity. A recently
published transcripitonal proﬁling study of 364 biopsies
obtained before and after hyperinsulinemeic-euglycemic
clampshowedsigniﬁcantoverepxressionoftheMIFreceptor.
Moreover, thiazolidoinedione treatment was associated with
asigniﬁcantdownregulationofthisgene[32].Clearevidence
for a direct link between obesity and insulin resistance may
be deduced from a very recent study in the obese showing
thatMIFmRNAexpressioninsubcutaneousadiposetissueis
positivelyassociatedwithadipocytesdiameterandnegatively
associated with peripheral and hepatic insulin action [23].
Importantly, freshly isolated mature adipocytes from subcu-
taneous, omental, and mammary depots can release MIF at
rates up to 10,000pg/mL × 24 hours, and MIF production of
the adipose depots is positively correlated with donor BMI
[22].
The above epidemiological and clinical studies suggest
an important link between MIF, obesity, the dysregulation
of glucose metabolism, and the development of insulin
resistance and T2D, but it remains unclear whether such
abnormalities in MIF and MIF receptor expression are
epiphenomena or casual factors. In the past few years,
studies in experimental models of disease have providedMediators of Inﬂammation 3
Table 1: Relationship between plasma MIF concentrations and body mass index in human studies. Studies are listed on basis of increasing
body mass index (BMI). The plasma MIF concentration is provided together with the number of male (m) and female (f) participants and
the major eﬀects observed. NS: not speciﬁed.
Average BMI Gender (m; f) MIF conc (ng/mL) Eﬀect observed Reference
22.6 versus 37.5 19; 21 1.2 versus 2.8
Positive correlation
of BMI with
plasma MIF conc.
and MIF mRNA of
MNC
[10]
22.6 versus 40.0 16; 16 1.3 versus 3.3
No correlation of
plasma MIF with
BMI and FFA; pos.
correlation with
HOMA
[11]
18–25 versus
30–48 0; 46 0.5 versus 1.9 Positive correlation
with BMI [12]
43.0 23; 48 8.4
MIF decreased
with weight loss
MIF conc. elevated
in women with
HRT
[13]
32.5 to 30.6 0; 31 16.0 to 5.4
MIF conc.
decreased with
weight loss
[14]
46.7 5; 22 0.2
MIF conc.
increased with
weight loss
[15]
27 versus 37 females NS
MIF production of
adipose tissue is
positively
correlated with
BMI
[22]
36 34 NS
mRNA conc
positively
associated with
adipocyte diameter
[23]
some conﬁrmatory data indicating a mechanistic role for
MIF in the comorbidities of obesity.
3. AnimalStudies
W h i l ear o l ef o rM I Fc o u l db ed e m o n s t r a t e di nv a r i o u s
settings of experimental type I diabetes [33–35], the involve-
ment of MIF in the pathogenesis of insulin resistance/T2D
has hardly been explored. Animal studies employing exper-
imental setting relevant for insulin resistance/T2D can be
subdivided in (1) studies investigating the role of MIF in
glucose metabolism and (2) studies elucidating the role
MIF in chronic WAT inﬂammation which are discussed
separately.
3.1. Impact of MIF on Glucose Metabolism. First evidence
for a role for MIF in glucose metabolism was suggested
by the immunohistochemical identiﬁcation of MIF within
the insulin-containing granules of the islets of Langerhans
[36]. The MIF content of pancreatic islets was increased by
high glucose concentrations, while immunoneutralization of
MIF in a perifusion system of Langerhans islets reduced the
ﬁrst and second phases of glucose-induced insulin secretion
by 39% and 31%, respectively. MIF addition to pancreatic
islets also augmented the glucose-induced insulin secretion
in response. A progressive decrease in MIF secretion or
sensitivity within the insulin-secreting cells thus may be
postulated to contribute to β-cell dysfunction, and an ele-
vation in systemic MIF in T2D may represent a physiologic
mechanism to overcome this defect [36].
The development of a systemic inﬂammatory response
during microbial infection or tissue invasion frequentlyleads
to a catabolic state. Transient hyperglycemia and insulin
resistance typically occur ﬁrst, but this may be followed
by a persistent state of lactate production and metabolic
acidosis, glycogen depletion, and hypoglycemia. Circulating
cytokines such as tumor necrosis factor (TNF) have long
been considered to provoke these metabolic abnormalities,
which unresolved, lead to protein wasting and cachexia.
In murine studies the catabolic eﬀect of TNF on muscle
was found to be mediated by MIF [37], as the admin-
istration of an anti-MIF antibody was found to abolish4 Mediators of Inﬂammation
Table 2: Relationship between plasma MIF concentrations, glucose intolerance, and T2D. The table provides the type of subjects (study
groups), the number of subjects per study group, and the plasma/serum MIF concentration together with the major eﬀects. IGT: impaired
glucose tolerance; PDR: proliferative diabetic retinopathy; ND: not determined.
Study groups n MIF conc (ng/mL) Eﬀect observed Reference
Control 79 5.2 MIF is elevated in
T2D subjects
[24]
T2D 79 20.7
Caucasians 24 <5.0 in 100% Fasting MIF conc.
are higher in Pima
Indians
[25]
Pima Indians 28 >5.0 in 39%
Normoglycemic 244 4.97 Positive association
of MIF with IGT
and T2D
independent of
CRP and IL-6
[26]
IGT 242 7.95
T2D 236 10.96
Noncases controls 1632 17.7 Females with MIF
genotype
rs1007888CC have
increased risk of
T2D
[16]
Future T2D 502 18.5
Control 257 5.8 Identiﬁcation of
MIF as a novel
immune marker to
predict progression
from IGT to T2D
[27]
Lifestyle intervention 265 6.2
Control 6 ND Increased kidney
CD74 expression
[28]
Diabetic nephropathy 20
Control 39 1.8 Increased MIF
levels in vitreous of
patients with PDR
[29]
PDR 32 11.9
Nondiabetics 24 1.1 Increased MIF
levels in patients
with retinopathy
[30]
PDR 40 6.3
Control diabetics 140 4.3 Higher MIF levels
in diabetics with
ulcer
[31]
Diabetics with ulcer 170 7.7
the TNF-induced hypoglycemia and the increase in muscle
F2, 6BP levels, which is a powerful allosteric regulator of
glycolysis and lactate production. Anti-MIF also prevented
these eﬀects in TNF-knockout mice administered bacterial
endotoxin, thus conﬁrming the intrinsic contribution of
MIF to these inﬂammation-induced metabolic changes
[37].
These ﬁndings were further extended once MIF-KO
mice became available. Hyperinsulinmeiceuglycemic clamp
studies in endotoxemic or TNF injected MIF-KO mice
showed these mice to exhibit normal blood glucose and
lactate responses [38]. MIF-KO mice also had increased
glucose uptake into white adipose tissue (WAT). Of note,
TNF had been shown previously to induce MIF production
from cultured adipocytes [39], and the intracellular content
of MIF mRNA and protein also has been shown to be
regulated by the intracellular glucose level [40]. Within
adipose tissue, MIF inhibited insulin signal transduction
[38]. MIF decreased the tyrosine phosphorylation of insuln
receptor substrate-1 (IRS-1) and its association with the
p85, and it inhibited the insulin-induced phosphorylation
of AKT, which is known to provide signals for the synthesis
of new glucose transporters. Overall, these studies support
the concept that MIF plays an important role in the
regulation of systemic glucose metabolism during infection
or tissue invasion. Moreover, they suggest that the previously
described action of TNF in insulin resistance is in fact
mediated by the downstream, autocrine/paracrine action of
MIF.
Finally, a recent study has identiﬁed a potentially critical
role for MIF in the cardiomyocyte response to ischemia
[41]. MIF was found to be released in the ischaemic
heart and stimulate the activation of AMPK, which is an
enzyme that senses the cellular energy state and aﬀects
diverse pathways to increase cellular ATP production and
limit energy consumption. Notably, human ﬁbroblasts with
a low-expression MIF allele have diminished MIF release
and AMPK activation during hypoxia, suggesting that the
predetermination of MIF genotype might predict risk in
patients with coronary artery disease.Mediators of Inﬂammation 5
3.2. Impact of MIF on Chronic WAT Inﬂammation. We
recently showed that genetic deletion of MIF reduces sys-
temic inﬂammation (SAA and ﬁbrinogen) and protects mice
against the development of glucose intolerance and insulin
resistance [42]. Development of disease was followed over
time (period of 52 weeks) in the LDL receptor deﬁcient
mouse model of combined insulin resistance and atheroscle-
rosis.MIFdeﬁciencyimprovedtheinsulinsensitivityofWAT
as quantiﬁed by PI3-kinase activity and AKT phosphoryla-
tion assays, and there was no corresponding eﬀect in liver or
muscle in this model. MIF deﬁciency did not aﬀect adipose
mass or obesity, but the adipocytes of MIF deﬁcient mice
however were found to be smaller in size, beginning at a
young age (12–18 weeks) [42].
An important event in the pathogenesis of insulin
resistance of WAT is the inﬁltration of macrophages causing
low-gradeadiposeinﬂammation[43]thatappearstodevelop
as a consequence of aging and/or high fat dietary stress
[44]. MIF-deﬁciency in the low density lipoprotein recep-
tor (LDLR) knock-out mouse model reduced macrophage
inﬁltration into WAT leading to fewer of the crown-like, his-
tologic structures that are typically seen in insulin resistant
adipose tissues. The eﬀect of MIF deﬁciency may be related
to the observed reduced expression of intracellular adhesion
molecule-1 (ICAM-1) and CD44 in WAT, that is, two pro-
teins that mediate monocyte/macrophage recruitment. An
MIF-dependent inﬂuence on adhesion molecule expression
and of macrophage tissue inﬁltration has been reported in
the context of cardiovascular disease (in absence of obesity)
[45–47].
Besides controlling local tissue-speciﬁc inﬂammation,
MIF is implicated in controlling systemic inﬂammation,
including the expression of risk factors of T2D. MIF aﬀects
the constitutive and interleukin-1 (IL-1)-induced expression
of SAA as well as the expression of IL-6 and human CRP
as demonstrated in human CRP transgenic mice [42]. MIF-
expressing mice also display higher levels of ﬁbrinogen [42],
which is a marker of the prothrombotic status and risk factor
for T2D. The stimulating eﬀect of MIF on the expression
of T2D risk factors (e.g., CRP) appears to reside within the
protein’s conformationally sensitive catalytic domain(s) [48]
because protein mutants of MIF which lack the intrinsic
oxidoreductase or tautomerase activity [49–51] also did not
stimulate human CRP expression in CRP transgenic mice
[42].
The speciﬁc role of MIF in the regulation of T2D risk
factors (e.g., the acute phase reactants CRP, SAA, ﬁbrinogen)
has yet to be systemically analyzed. Burger-Kentischer and
coworkersshowedthatimmunoneutralization ofMIFlowers
plasma ﬁbrinogen and IL-6 levels and reduces the expression
level of CCAAT-enhancer-binding protein beta (C/EBPβ)
[52] and a similar eﬀect on C/EBPβ was reported by others
[38]. C/EBPβ is a positive regulator of IL-6, ﬁbrinogen, SAA,
and CRP but also a transcription factor for the adhesion
molecules VCAM-1 and ICAM-1 [45, 53], and MIF is
coexpressed with C/EBPβ-regulated proteases (e.g., MMP-9)
[54] that have been associated with hyperexpression of IL-
6 and IL-8 and the development of renal and cardiovascular
complications [55, 56].
Finally, the identiﬁcation of prevalent, functional poly-
morphisms in MIF, which show signiﬁcant population
stratiﬁcation [20], prompts closer examination of the con-
tribution of the MIF locus as a risk factor for T2D, obesity,
and cardiovascular disease.
Acknowledgment
Grant support has been received from the NIH and the
Brookdale Foundation (to the second author) as well as
from the TNO research program “Humanized models of
inﬂammatory metabolic diseases” (to the ﬁrst author).
References
[1] T. Kelly, W. Yang, C.-S. Chen, K. Reynolds, and J. He,
“Global burden of obesity in 2005 and projections to 2030,”
International Journal of Obesity, vol. 32, no. 9, pp. 1431–1437,
2008.
[2] P. S. Yusuf, S. Hawken, S. Ounpuu, et al., “Eﬀect of potentially
modiﬁable risk factors associated with myocardial infarction
in 52 countries (the INTERHEART study): case-control
study,” The Lancet, vol. 364, no. 9438, pp. 937–952, 2004.
[3] J.-P. Despres, I. Lemieux, J. Bergeron, et al., “Abdominal
obesity and the metabolic syndrome: contribution to global
cardiometabolic risk,” Arteriosclerosis, Thrombosis, and Vascu-
lar Biology, vol. 28, no. 6, pp. 1039–1049, 2008.
[4] H. Xu, G. T. Barnes, Q. Yang, et al., “Chronic inﬂammation in
fat plays a crucial role in the development of obesity-related
insulin resistance,” Journal of Clinical Investigation, vol. 112,
no. 12, pp. 1821–1830, 2003.
[5] J.-P. Despr´ es, “Is visceral obesity the cause of the metabolic
syndrome?”AnnalsofMedicine,vol.38,no.1,pp.52–63,2006.
[6] A.Zernecke,J.Bernhagen,andC.Weber,“Macrophagemigra-
tion inhibitory factor in cardiovascular disease,” Circulation,
vol. 117, no. 12, pp. 1594–1602, 2008.
[7] H. Y. Lan, “Role of macrophage migration inhibition factor in
kidney disease,” Nephron—Experimental Nephrology, vol. 109,
no. 3, pp. e79–e83, 2008.
[8] H. Flaster, J. Bernhagen, T. Calandra, and R. Bucala,
“The macrophage migration inhibitory factor-glucocorticoid
dyad: regulation of inﬂammation and immunity,” Molecular
Endocrinology, vol. 21, no. 6, pp. 1267–1280, 2007.
[9] H. Lue, R. Kleemann, T. Calandra, T. Roger, and J. Bernhagen,
“Macrophage migration inhibitory factor (MIF): mechanisms
of action and role in disease,” Microbes and Infection, vol. 4,
no. 4, pp. 449–460, 2002.
[10] P. Dandona, A. Aljada, H. Ghanim, et al., “Increased plasma
concentration of macrophage Migration Inhibitory Factor
(MIF) and MIF mRNA in mononuclear cells in the obese
and the suppressive action of metformin,” Journal of Clinical
Endocrinology and Metabolism, vol. 89, no. 10, pp. 5043–5047,
2004.
[11] H. Ghanim, A. Aljada, D. Hofmeyer, T. Syed, P. Mohanty, and
P. Dandona, “Circulating mononuclear cells in the obese are
in a proinﬂammatory state,” Circulation, vol. 110, no. 12, pp.
1564–1571, 2004.
[12] M. Sumarac-Dumanovic, D. Stevanovic, A. Ljubic, et al.,
“Increased activity of interleukin-23/interleukin-17 proin-
ﬂammatory axis in obese women,” International Journal of
Obesity, vol. 33, no. 1, pp. 151–156, 2009.6 Mediators of Inﬂammation
[13] T. S. Church, M. S. Willis, E. L. Priest, et al., “Obesity,
macrophage migration inhibitory factor, and weight loss,”
International Journal of Obesity, vol. 29, no. 6, pp. 675–681,
2005.
[14] W.H.-H.Sheu,T.-M.Chang,W.-J.Lee,etal.,“Eﬀectofweight
loss on proinﬂammatory state of mononuclear cells in obese
women,” Obesity, vol. 16, no. 5, pp. 1033–1038, 2008.
[15] F. M. H. Van Dielen, W. A. Buurman, M. Hadfoune, J.
Nijhuis, and J. W. Greve, “Macrophage inhibitory factor,
plasminogen activator inhibitor-1, other acute phase proteins,
and inﬂammatory mediators normalize as a result of weight
loss in morbidly obese subjects treated with gastric restrictive
surgery,”JournalofClinicalEndocrinologyandMetabolism,vol.
89, no. 8, pp. 4062–4068, 2004.
[ 1 6 ]C .H e r d e r ,N .K l o p p ,J .B a u m e r t ,e ta l . ,“ E ﬀect of macrophage
migration inhibitory factor (MIF) gene variants and MIF
serum concentrations on the risk of type 2 diabetes: results
from the MONICA/KORA Augsburg Case-Cohort Study,
1984–2002,” Diabetologia, vol. 51, no. 2, pp. 276–284, 2008.
[17] N. Petrovsky, L. Socha, D. Silva, A. B. Grossman, C. Metz,
and R. Bucala, “Macrophage migration inhibitory factor
exhibits a pronounced circadian rhythm relevant to its role
as a glucocorticoid counter-regulator,” Immunology and Cell
Biology, vol. 81, no. 2, pp. 137–143, 2003.
[18] S. Sakaue, S. Ishimaru, N. Hizawa, et al., “Promoter polymor-
phism in the macrophage migration inhibitory factor gene is
associated with obesity,” International Journal of Obesity, vol.
30, no. 2, pp. 238–242, 2006.
[19] J. A. Baugh, S. Chitnis, S. C. Donnelly, et al., “A func-
tional promoter polymorphism in the macrophage migration
inhibitory factor (MIF) gene associated with disease severity
in rheumatoid arthritis,” Genes and Immunity,v o l .3 ,n o .3 ,
pp. 170–176, 2002.
[20] X. B. Zhong, L. Leng, A. Beitin, et al., “Simultaneous detection
of microsatellite repeats and SNPs in the macrophage migra-
tion inhibitory factor (MIF) gene by thin-ﬁlm biosensor chips
and application to rural ﬁeld studies,” Nucleic Acids Research,
vol. 33, no. 13, article e121, 2005.
[ 2 1 ]T .R .D .J .R a d s t a k e ,F .C .G .J .S w e e p ,P .W e l s i n g ,e ta l . ,
“Correlation of rheumatoid arthritis severity with the genetic
functional variants and circulating levels of macrophage
migration inhibitory factor,” Arthritis and Rheumatism, vol.
52, no. 10, pp. 3020–3029, 2005.
[22] T. Skurk, C. Herder, I. Kraft, S. Muller-Scholze, H. Hauner,
and H. Kolb, “Production and release of macrophage migra-
tioninhibitoryfactorfromhumanadipocytes,” Endocrinology,
vol. 146, no. 3, pp. 1006–1011, 2005.
[23] J. Koska, N. Stefan, S. Dubois, et al., “mRNA concentrations of
MIF in subcutaneous abdominal adipose cells are associated
with adipocyte size and insulin action,” International Journal
of Obesity, vol. 33, no. 8, pp. 842–850, 2009.
[24] N. Yabunaka, J. Nishihira, Y. Mizue, et al., “Elevated serum
content of macrophage migration inhibitory factor in patients
with type 2 diabetes,” Diabetes Care, vol. 23, no. 2, pp. 256–
258, 2000.
[25] B. Vozarova, N. Stefan, R. Hanson, et al., “Plasma concentra-
tions of macrophage migration inhibitory factor are elevated
in Pima Indians compared to Caucasians and are associated
withinsulinresistance,”Diabetologia,vol.45,no.12,pp.1739–
1741, 2002.
[ 2 6 ] C .H e r d e r ,H .K o l b ,W .K o e n i g ,e ta l . ,“ A s s o c i a t i o no fs y s t e m i c
concentrations of macrophage migration inhibitory factor
with impaired glucose tolerance and type 2 diabetes: results
from the Cooperative Health Research in the Region of
Augsburg, Survey 4 (KORA S4),” Diabetes Care, vol. 29, no.
2, pp. 368–371, 2006.
[27] C. Herder, M. Peltonen, W. Koenig, et al., “Systemic immune
mediators and lifestyle changes in the prevention of type 2
diabetes: results from the Finnish Diabetes Prevention Study,”
Diabetes, vol. 55, no. 8, pp. 2340–2346, 2006.
[28] M. D. Sanchez-Nino, A. B. Sanz, P. Ihalmo, et al., “The MIF
receptor CD74 in diabetic podocyte injury,” Journal of the
American Society of Nephrology, vol. 20, no. 2, pp. 353–362,
2009.
[29] Y. Mitamura, S. Takeuchi, A. Matsuda, Y. Tagawa, Y. Mizue,
and J. Nishihira, “Macrophage migration inhibitory factor
levels in the vitreous of patients with proliferative diabetic
retinopathy,” British Journal of Ophthalmology, vol. 84, no. 6,
pp. 636–639, 2000.
[30] A. Tashimo, Y. Mitamura, S. Nagai, et al., “Aqueous levels
of macrophage migration inhibitory factor and monocyte
chemotactic protein-1 in patients with diabetic retinopathy,”
Diabetic Medicine, vol. 21, no. 12, pp. 1292–1297, 2004.
[31] C. Weigelt, B. Rose, U. Poschen, et al., “Immune mediators
in patients with acute diabetic foot syndrome,” Diabetes Care,
vol. 32, no. 8, pp. 1491–1496, 2009.
[32] D. D. Sears, G. Hsiao, A. Hsiao, et al., “Mechanisms of
human insulin resistance and thiazolidinedione-mediated
insulin sensitization,” Proceedings of the National Academy of
Sciences of the United States of America, vol. 106, no. 44, pp.
18745–18750, 2009.
[33] J.Bojunga,K.Kusterer,M.Bacher,R.Kurek,K.-H.Usadel,and
H. Renneberg, “Macrophage migration inhibitory factor and
development of type-1 diabetes in non-obese diabetic mice,”
Cytokine, vol. 21, no. 4, pp. 179–186, 2003.
[34] I. Cvetkovic, Y. Al-Abed, D. Miljkovic, et al., “Critical role
of macrophage migration inhibitory factor activity in exper-
imental autoimmune diabetes,” Endocrinology, vol. 146, no. 7,
pp. 2942–2951, 2005.
[35] S. Stosic-Grujicic, I. Stojanovic, D. Maksimovic-Ivanic, et al.,
“Macrophage migration inhibitory factor (MIF) is necessary
for progression of autoimmune diabetes mellitus,” Journal of
Cellular Physiology, vol. 215, no. 3, pp. 665–675, 2008.
[36] G. Waeber, T. Calandra, R. Roduit, et al., “Insulin secretion is
regulated by the glucose-dependent production of islet β cell
macrophage migration inhibitory factor,” Proceedings of the
National Academy of Sciences of the United States of America,
vol. 94, no. 9, pp. 4782–4787, 1997.
[37] F. Benigni, T. Atsumi, T. Calandra, et al., “The proinﬂam-
matory mediator macrophage migration inhibitory factor
induces glucose catabolism in muscle,” Journal of Clinical
Investigation, vol. 106, no. 10, pp. 1291–1300, 2000.
[38] T. Atsumi, Y.-R. Cho, L. Leng, et al., “The proinﬂammatory
cytokine macrophage migration inhibitory factor regulates
glucose metabolism duringsystemic inﬂammation,” Journal of
Immunology, vol. 179, no. 8, pp. 5399–5406, 2007.
[39] J. Hirokawa, S. Sakaue, S. Tagami, et al., “Identiﬁcation of
macrophage migration inhibitory factor in adipose tissue and
its induction by tumor necrosis factor-α,” Biochemical and
Biophysical Research Communications, vol. 235, no. 1, pp. 94–
98, 1997.
[40] S. Sakaue, J. Nishihira, J. Hirokawa, et al., “Regulation of
macrophage migration inhibitory factor (MIF) expression
by glucose and insulin in adipocytes in vitro,” Molecular
Medicine, vol. 5, no. 6, pp. 361–371, 1999.
[41] E. J. Miller, J. Li, L. Leng, et al., “Macrophage migration
inhibitory factor stimulates AMP-activated protein kinase inMediators of Inﬂammation 7
the ischaemic heart,” Nature, vol. 451, no. 7178, pp. 578–582,
2008.
[42] L.Verschuren,T.Kooistra,J.Bernhagen,etal.,“MIFdeﬁciency
reduces chronic inﬂammation in white adipose tissue and
impairs the development of insulin resistance, glucose intol-
erance, and associated atherosclerotic disease,” Circulation
Research, vol. 105, no. 1, pp. 99–107, 2009.
[43] J. G. Neels and J. M. Olefsky, “Inﬂamed fat: what starts the
ﬁre?” Journal of Clinical Investigation, vol. 116, no. 1, pp. 33–
35, 2006.
[44] H. Carlsen, F. Haugen, S. Zadelaar, et al., “Diet-induced
obesityincreases NF-κB signalinginreporter mice,” Genesand
Nutrition, vol. 4, no. 3, pp. 215–222, 2009.
[45] M. A. Amin, C. S. Haas, K. Zhu, et al., “Migration inhibitory
factor up-regulates vascular cell adhesion molecule-1 and
intercellular adhesion molecule-1 via Src, PI3 kinase, and
NFκB,” Blood, vol. 107, no. 6, pp. 2252–2261, 2006.
[46] J. Bernhagen, R. Krohn, H. Lue, et al., “MIF is a noncognate
ligand of CXC chemokine receptors in inﬂammatory and
atherogenic cell recruitment,” Nature Medicine, vol. 13, no. 5,
pp. 587–596, 2007.
[47] L. Verschuren, R. Kleemann, E. H. Oﬀerman, et al., “Eﬀect of
low dose atorvastatin versus diet-induced cholesterol lowering
on atherosclerotic lesion progression and inﬂammation in
apolipoprotein E
∗3-Leiden transgenic mice,” Arteriosclerosis,
Thrombosis, and Vascular Biology, vol. 25, no. 1, pp. 161–167,
2005.
[48] G. Fingerle-Rowson, D. R. Kaleswarapu, C. Schlander, et al.,
“A tautomerase-null macrophage migration-inhibitory factor
(MIF) gene knock-in mouse model reveals that protein inter-
actions and not enzymatic activity mediate MIF-dependent
growthregulation,”MolecularandCellularBiology,vol.29,no.
7, pp. 1922–1932, 2009.
[49] R. Kleemann, A. Kapurniotu, R. W. Frank, et al., “Disulﬁde
analysis reveals a role for macrophage migration inhibitory
factor (MIF) as thiol-protein oxidoreductase,” Journal of
Molecular Biology, vol. 280, no. 1, pp. 85–102, 1998.
[50] R. Kleemann, H. Rorsman, E. Rosengren, R. Mischke, N.
T. Mai, and J. Bernhagen, “Dissection of the enzymatic and
immunologic functions of macrophage migration inhibitory
factor: full immunologic activity of N-terminally truncated
mutants,” European Journal of Biochemistry, vol. 267, no. 24,
pp. 7183–7192, 2000.
[51] R. Kleemann, A. Kapurniotu, R. Mischke, J. Held, and J.
Bernhagen, “Characterization of catalytic centre mutants of
macrophage migration inhibitory factor (MIF) and compar-
ison to Cys81Ser MIF,” European Journal of Biochemistry, vol.
261, no. 3, pp. 753–766, 1999.
[52] A. Burger-Kentischer, H. Gobel, R. Kleemann, et al.,
“Reduction of the aortic inﬂammatory response in sponta-
neous atherosclerosis by blockade of macrophage migration
inhibitory factor (MIF),” Atherosclerosis, vol. 184, no. 1, pp.
28–38, 2006.
[53] A. M. Carter, “Inﬂammation, thrombosis and acute coronary
syndromes,” Diabetes and Vascular Disease Research, vol. 2, no.
3, pp. 113–121, 2005.
[54] L. Verschuren, J. H. N. Lindeman, J. H. van Bockel, H.
Abdul-Hussien,T.Kooistra,andR.Kleemann,“Up-regulation
and coexpression of MIF and matrix metalloproteinases in
human abdominal aortic aneurysms,” Antioxidants and Redox
Signaling, vol. 7, no. 9-10, pp. 1195–1202, 2005.
[55] J. H. N. Lindeman, H. Abdul-Hussien, A. F. M. Schaa-
pherder, et al., “Enhanced expression and activation of pro-
inﬂammatory transcription factors distinguish aneurysmal
from atherosclerotic aorta: IL-6- and IL-8-dominated inﬂam-
matory responses prevail in the human aneurysm,” Clinical
Science, vol. 114, no. 11-12, pp. 687–697, 2008.
[56] J. H. N. Lindeman, H. Abdul-Hussien, J. H. van Bockel, R.
Wolterbeek, and R. Kleemann, “Clinical trial of doxycycline
for matrix metalloproteinase-9 inhibition in patients with an
abdominal aneurysm doxycycline selectively depletes aortic
wall neutrophils and cytotoxic t cells,” Circulation, vol. 119,
no. 16, pp. 2209–2216, 2009.